Log In
Print
BCIQ
Print
Print this Print this
 

cerium nitrate/silver sulfadiazine (Flammacerium)

  Manage Alerts
Collapse Summary General Information
Company Sinclair IS Pharma plc
DescriptionCream containing 1% silver sulfadiazine and 2.2% cerium nitrate
Molecular Target
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard Indication Infectious (unspecified)
Indication DetailsTreat and prevent infections in burn wounds
Regulatory Designation

U.S. - Orphan Drug (Treat and prevent infections in burn wounds)

Partner

Hikma Pharmaceuticals plc


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

3

$25.7M

$25.7M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today